Reqorsa Immunogene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Genprex bags FDA orphan drug designation for lung cancer therapy

Genprex has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead candidate, Reqorsa immunogene therapy (quaratusugene ozeplasmid), for the treatment of small cell lung cancer (SCLC).

United statesRodney varnerGenentech tecentriqReqorsa immunogeneOrphan drug designationDrug designationBio developmentsFood and drug administrationLung cancer

FDA Grants Orphan Drug Designation to Quratusugene Ozeplasmid for Small Cell Lung Cancer

FDA Grants Orphan Drug Designation to Quratusugene Ozeplasmid for Small Cell Lung Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesRodney varnerReqorsa immunogene

FDA Grants Fast Track Status to Quaratusugene Ozeplasmid Plus Atezolizumab in ES-SCLC

The FDA has granted fast track designation to the combination of quaratusugene ozeplasmid and atezolizumab as maintenance therapy in patients with extensive-stage small cell lung cancer whose disease did not progress after receiving initial standard treatment with atezolizumab and chemotherapy.

Reqorsa immunogeneRodney varnerGenprex inc

Genprex Shares Rise 8% on FDA Review of Reqorsa Trial

Genprex Shares Rise 8% on FDA Review of Reqorsa Trial
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

Chris wackGenprex incDow jones company incDrug administrationReqorsa immunogeneTrack designationDow jonesகிறிஸ் வ்யாக்டோ ஜோன்ஸ் நிறுவனம் இன்க்டிராக் பதவிடோ ஜோன்ஸ்